The stock has a 36-month beta value of 1.02. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 0.66M, and at present, short sellers hold a 55.80% of that float. On February 24, 2025, the average trading volume of RNAZ was 1.69M shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has gone decline by -13.82 in comparison to its previous close of 9.37, however, the company has experienced a -24.25% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-02-06 that No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes available.
RNAZ’s Market Performance
TransCode Therapeutics Inc (RNAZ) has seen a -24.25% fall in stock performance for the week, with a 131.38% gain in the past month and a -25.85% plunge in the past quarter. The volatility ratio for the week is 14.99%, and the volatility levels for the past 30 days are at 43.13% for RNAZ. The simple moving average for the past 20 days is -12.27% for RNAZ’s stock, with a -54.05% simple moving average for the past 200 days.
RNAZ Trading at 26.62% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.83% of loss for the given period.
Volatility was left at 43.13%, however, over the last 30 days, the volatility rate increased by 14.99%, as shares surge +46.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.46% upper at present.
During the last 5 trading sessions, RNAZ fell by -24.25%, which changed the moving average for the period of 200-days by -70.16% in comparison to the 20-day moving average, which settled at $9.20. In addition, TransCode Therapeutics Inc saw 139.61% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -103.97. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -181.32.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 5.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
To sum up, TransCode Therapeutics Inc (RNAZ) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
